{"id":"cggv:5ca11e8c-6703-4be5-a8c2-82e6dcc865e4v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:5ca11e8c-6703-4be5-a8c2-82e6dcc865e4_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10007","date":"2020-09-01T00:00:00Z","role":"Publisher"},{"id":"cggv:5ca11e8c-6703-4be5-a8c2-82e6dcc865e4_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10007","date":"2019-05-21T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"cggv:5ca11e8c-6703-4be5-a8c2-82e6dcc865e4_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:5ca11e8c-6703-4be5-a8c2-82e6dcc865e4_seg_el","type":"EvidenceLine","specifiedBy":"GeneValiditySegregationEvidencCriteria","strengthScore":1.5},{"id":"cggv:5ca11e8c-6703-4be5-a8c2-82e6dcc865e4_ar_el","type":"EvidenceLine","evidence":[{"id":"cggv:d7e90acd-5ff3-4e8e-a350-fb3be2c5a81f_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:02467d19-12ed-4bf4-b33e-677e8792e8ff","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"detectionMethod":"Sequenced FGF3","firstTestingMethod":"PCR","phenotypes":["obo:HP_0000687","obo:HP_0011372","obo:HP_0011476","obo:HP_0000369","obo:HP_0040080","obo:HP_0000430","obo:HP_0000494"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:d7e90acd-5ff3-4e8e-a350-fb3be2c5a81f_variant_evidence_item","type":"MolecularSequenceObservation","allele":[{"id":"cggv:ea275539-0e21-4ae4-88cc-d49c361a4f2e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005247.2(FGF3):c.310C>T (p.Arg104Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/13838"}},{"id":"cggv:a3732409-6acf-4cf3-b03b-8ff1749bc71d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005247.2(FGF3):c.146A>G (p.Tyr49Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/29816"}}],"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/21480479","type":"dc:BibliographicResource","dc:abstract":"We report on the first cases of FGF3 compound heterozygotes in two European families from non-consanguineous marriages, affected with labyrinthine aplasia, microtia, and microdontia (LAMM) Syndrome. Three not previously described mutations (p.W153VfsX51, p.Y106C, and p.Y49C) and a recurrent one (p.R104X) were found. Analysis of 50 unrelated control subjects (100 chromosomes) of the same European background did not show any of the two newly reported missense variations. We confirm the absence of otodental syndrome in heterozygous carriers, but report unilateral microtia in one of them. We also report on the involvement of the middle ear structures in LAMM Syndrome.","dc:creator":"Sensi A","dc:date":"2011","dc:title":"LAMM syndrome with middle ear dysplasia associated with compound heterozygosity for FGF3 mutations."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21480479","rdfs:label":"Sensi Patient B"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5,"dc:description":"Variant is present in 2/30616 South Asian alleles and 4/113766 European (Non-Finnish) alleles in gnomAD. This variant was found to segregate with LAMM syndrome in at least two additional families (Tekin 2007 17236138, Riazuddin 2011 21306635)."},{"id":"cggv:dcb15241-bbeb-499c-9f49-abb23a951605_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:566615a7-4dd6-40a6-a133-dfbce2b1eef1","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":4,"detectionMethod":"sequenced candidate genes in the linkage region","firstTestingMethod":"Linkage analysis","phenotypes":["obo:HP_0011266","obo:HP_0005274","obo:HP_0040080","obo:HP_0000369","obo:HP_0011372","obo:HP_0000687","obo:HP_0008527","obo:HP_0000691","obo:HP_0000377","obo:HP_0011476"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:dcb15241-bbeb-499c-9f49-abb23a951605_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:0422083c-c9b5-401c-8acf-4c41fe8cc047","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005247.2(FGF3):c.196G>T (p.Gly66Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/13840"}},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/18701883","type":"dc:BibliographicResource","dc:abstract":"We identified a homozygous missense mutation (c.196G-->T) in fibroblast growth factor 3 (FGF3) in 21 affected individuals from a large extended consanguineous Saudi family, phenotypically characterized by autosomal recessive syndromic congenital sensorineural deafness, microtia and microdontia. All affected family members are descendents of a common ancestor who had lived six generations ago in a geographically isolated small village. This is the second report of FGF3 involvement in syndromic deafness in humans, and independently confirms the gene's positive role in inner ear development. The c.196G-->T mutation results in substitution of glycine by cysteine at amino acid 66 (p.G66C). This residue is conserved in several species and across 18 FGF family members. Conserved glycine/proline residues are central to the 'beta-trefoil fold' characteristic of the secondary structure of FGF family proteins and substitution of these residues is likely to disrupt structure and consequently function.","dc:creator":"Alsmadi O","dc:date":"2009","dc:title":"Syndromic congenital sensorineural deafness, microtia and microdontia resulting from a novel homoallelic mutation in fibroblast growth factor 3 (FGF3)."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/18701883","rdfs:label":"Arab Family Proband"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5,"dc:description":"Variant is absent from gnomAD. Downgraded because the family is from an isolated village, and consanguinity is possible"},{"id":"cggv:bb994dce-1481-4227-91a8-2dad19716b9b_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:63a58fd4-7df8-4fc5-bb2e-7c9b9895add8","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":2,"detectionMethod":"FGF3 sequenced","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0010609","obo:HP_0008527","obo:HP_0040080","obo:HP_0011372","obo:HP_0011476","obo:HP_0011266"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:bb994dce-1481-4227-91a8-2dad19716b9b_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:29473480-4e25-4812-8748-8abf5e1faea9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005247.2(FGF3):c.255delT (p.Ile85Metfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/13842"}},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/18435799","type":"dc:BibliographicResource","dc:abstract":"Homozygous mutations in the fibroblast growth factor 3 (FGF3) gene have recently been discovered in an autosomal recessive form of syndromic deafness characterized by complete labyrinthine aplasia (Michel aplasia), microtia, and microdontia (OMIM 610706 - LAMM). In order to better characterize the phenotypic spectrum associated with FGF3 mutations, we sequenced the FGF3 gene in 10 unrelated families in which probands had congenital deafness associated with various inner ear anomalies, including Michel aplasia, with or without tooth or external ear anomalies. FGF3 sequence changes were not found in eight unrelated probands with isolated inner ear anomalies or with a cochlear malformation along with auricle and tooth anomalies. We identified two new homozygous FGF3 mutations, p.Leu6Pro (c.17T>C) and p. Ile85MetfsX15 (c.254delT), in four subjects from two unrelated families with LAMM. The p.Leu6Pro mutation occurred within the signal site of FGF3 and is predicted to impair its secretion. The c.254delT mutation results in truncation of FGF3. Both mutations completely co-segregated with the phenotype, and heterozygotes did not have any of the phenotypic findings of LAMM. Some affected children had large skin tags on the upper side of the auricles, which is a distinctive clinical component of the syndrome. Enlarged collateral emissary veins associated with stenosis of the jugular foramen were noted on computerized tomographies of most affected subjects with FGF3 mutations. However, similar venous anomalies were also detected in persons with non-syndromic Michel aplasia, suggesting that a direct causative role of impaired FGF3 signaling is unlikely.","dc:creator":"Tekin M","dc:date":"2008","dc:title":"Homozygous FGF3 mutations result in congenital deafness with inner ear agenesis, microtia, and microdontia."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/18435799","rdfs:label":"Family 1 Proband"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2,"dc:description":"Variant is absent from gnomAD. Variant confirmed heterozygous in parents and NMD is predicted based on location of the frameshift within the protein."},{"id":"cggv:f925799c-ec56-4917-b7dd-b1812e00e1cb_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:e7854a2f-9a43-4a43-8523-47ead7b5c531","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":8,"detectionMethod":"FGF3 sequenced","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"absence of cochleovestibular nerve","phenotypes":["obo:HP_0000691","obo:HP_0002194","obo:HP_0008527","obo:HP_0011372","obo:HP_0000687","obo:HP_0011476","obo:HP_0011266"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"cggv:f925799c-ec56-4917-b7dd-b1812e00e1cb_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:ea275539-0e21-4ae4-88cc-d49c361a4f2e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/17236138","type":"dc:BibliographicResource","dc:abstract":"We identified nine individuals from three unrelated Turkish families with a unique autosomal recessive syndrome characterized by type I microtia, microdontia, and profound congenital deafness associated with a complete absence of inner ear structures (Michel aplasia). We later demonstrated three different homozygous mutations (p.S156P, p.R104X, and p.V206SfsX117) in the fibroblast growth factor 3 (FGF3) gene in affected members of these families, cosegregating with the autosomal recessive transmission as a completely penetrant phenotype. These findings demonstrate the involvement of FGF3 mutations in a human malformation syndrome for the first time and contribute to our understanding of the role this gene plays in embryonic development. Of particular interest is that the development of the inner ear is completely disturbed at a very early stage--or the otic vesicle is not induced at all--in all of the affected individuals who carried two mutant FGF3 alleles.","dc:creator":"Tekin M","dc:date":"2007","dc:title":"Homozygous mutations in fibroblast growth factor 3 are associated with a new form of syndromic deafness characterized by inner ear agenesis, microtia, and microdontia."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/17236138","rdfs:label":"B Proband"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5,"dc:description":"Variant is present in 2/30616 South Asian alleles and 4/113766 European (Non-Finnish) alleles in gnomAD. This variant was found to segregate with LAMM syndrome in at least two additional families (Riazuddin 2011 21306635, Sensi 2011 21480479). Downgraded for homozygosity."},{"id":"cggv:d7903d07-176f-4f1f-b47f-79f04247f053_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:8031507b-79c7-4ee6-abbf-9ff7f993451d","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":21,"detectionMethod":"FGF3 sequenced","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"jugular foraminal stenosis","phenotypes":["obo:HP_0000687","obo:HP_0011372","obo:HP_0000448","obo:HP_0011476","obo:HP_0040080","obo:HP_0008527","obo:HP_0000691","obo:HP_0010609","obo:HP_0000494","obo:HP_0011266"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:d7903d07-176f-4f1f-b47f-79f04247f053_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:034f8a85-827d-4718-adf4-4199bfbaddb1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005247.2(FGF3):c.17T>C (p.Leu6Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/13841"}},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/18435799"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/18435799","rdfs:label":"Family 2 Proband"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5,"dc:description":"Variant is absent from gnomAD. Downgraded because family is consanguineous, only FGF3 was sequenced, and there is no functional evidence for the pathogenicity of the variant."},{"id":"cggv:05659e10-634e-416e-88ab-c29e00f818e9_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:aec70178-d1e1-45f6-b0c6-a96a07592333","type":"Proband","ageType":"cggv","ageUnit":"cggv","detectionMethod":"FGF3 screening","firstTestingMethod":"PCR","phenotypes":["obo:HP_0011266","obo:HP_0011476","obo:HP_0000698","obo:HP_0000691"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"cggv:05659e10-634e-416e-88ab-c29e00f818e9_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:af8f8c4b-2693-4bd5-bd8f-87aa0b798ee9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005247.2(FGF3):c.394delC (p.Arg132Glyfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/38386"}},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/21306635","type":"dc:BibliographicResource","dc:abstract":"Recessive mutations of fibroblast growth factor 3 (FGF3) can cause LAMM syndrome (OMIM 610706), characterized by fully penetrant complete labyrinthine aplasia, microtia and microdontia.","dc:creator":"Riazuddin S","dc:date":"2011","dc:title":"Variable expressivity of FGF3 mutations associated with deafness and LAMM syndrome."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21306635","rdfs:label":"PKDF887 Proband"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5,"dc:description":"Variant is absent from gnomAD. Downgraded for consanguinity of family and because the frameshift occurs in the last exon so NMD is not predicted to occur. There is no functional evidence for the pathogenicity of this variant."},{"id":"cggv:1c87d30e-85ba-4302-a7e1-5a22ca5c21a3_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:eddef930-e406-4f29-8231-a0e2a2384e36","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":14,"detectionMethod":"SNP analysis, sequencing of FGF3","phenotypeFreeText":"absence of cochleovestibular nerve","phenotypes":["obo:HP_0011372","obo:HP_0011476","obo:HP_0002194","obo:HP_0000687","obo:HP_0011266","obo:HP_0000691","obo:HP_0008527"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"cggv:1c87d30e-85ba-4302-a7e1-5a22ca5c21a3_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:6939fbd0-93ce-40da-be5f-e03c6e59dfd7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005247.2(FGF3):c.466T>C (p.Ser156Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/13837"}},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/17236138"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/17236138","rdfs:label":"A Proband"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5,"dc:description":"Variant is absent from gnomAD. Downgraded because family is consanguineous"},{"id":"cggv:bc4c5d39-4e31-434a-af28-0ad7cab51650_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:1ca13c7b-f80a-4aae-b572-0e9b605a8bf0","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":13,"detectionMethod":"FGF3 sequenced","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"absence of cochleovestibular nerve","phenotypes":["obo:HP_0011372","obo:HP_0011476","obo:HP_0000687","obo:HP_0008527","obo:HP_0002194","obo:HP_0011266","obo:HP_0000691"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:bc4c5d39-4e31-434a-af28-0ad7cab51650_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:150c0454-e7c3-42c0-967a-57170893cb10","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005247.2(FGF3):c.616delG (p.Val206Serfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/13839"}},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/17236138"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/17236138","rdfs:label":"C Proband"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1,"dc:description":"Variant is absent from gnomAD. Downgraded because the protein is not predicted to undergo NMD and not functional evidence has been reported. Additionally, only FGF3 was sequenced in this patient."},{"id":"cggv:030386e1-4ea1-425a-bca8-aac105652d91_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:67bf7b97-e93a-4b75-9b78-8158d53ecee6","type":"Proband","ageType":"cggv","ageUnit":"cggv","detectionMethod":"screened for FGF3","firstTestingMethod":"PCR","phenotypes":["obo:HP_0000691","obo:HP_0011476","obo:HP_0011266","obo:HP_0000698"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:030386e1-4ea1-425a-bca8-aac105652d91_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:ea275539-0e21-4ae4-88cc-d49c361a4f2e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21306635"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21306635","rdfs:label":"PKDF295 Proband"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5,"dc:description":"Variant is present in 2/30616 South Asian alleles and 4/113766 European (Non-Finnish) alleles in gnomAD. This variant was found to segregate with LAMM syndrome in at least two additional families (Tekin 2007 17236138, Sensi 2011 21480479).Downgrade for homozygosity"},{"id":"cggv:09058805-68e0-42e0-aa4e-ca1100f3a8ca_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:650ecad9-622b-4200-98cb-2bb91ca7a7ae","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":12,"detectionMethod":"sequenced FGF3","firstTestingMethod":"PCR","phenotypes":["obo:HP_0011372","obo:HP_0000430","obo:HP_0011476","obo:HP_0000494","obo:HP_0011266","obo:HP_0000399","obo:HP_0000426","obo:HP_0000490","obo:HP_0000691","obo:HP_0000687"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"cggv:09058805-68e0-42e0-aa4e-ca1100f3a8ca_variant_evidence_item","type":"MolecularSequenceObservation","allele":[{"id":"cggv:62ed28c8-c783-482c-a874-2ff491d4f9bc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005247.2(FGF3):c.457_458delTG (p.Trp153Valfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/29818"}},{"id":"cggv:05c67542-5b8e-4e5c-bbf4-487eb9c877d1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005247.2(FGF3):c.317A>G (p.Tyr106Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/29817"}}],"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21480479"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21480479","rdfs:label":"Sensi Family A Proband"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5,"dc:description":"Downgraded for missense variant without substantial evidence for pathogenicity\n2 sibs, male and female of non-consanguineous parents\nAffecteds have microtia, microdontia, sensorineural hearing loss\nOnly sequenced FGF3\nMale sib was confirmed to have compound het p.Tyr106Cys, and p.Trp153ValfsX51"},{"id":"cggv:a13ff342-794e-4b45-9803-7544026f5378_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:4e8d0f40-8096-400e-847b-29e863d67073","type":"Proband","ageType":"cggv","ageUnit":"cggv","detectionMethod":"screened for FGF3","firstTestingMethod":"PCR","phenotypes":["obo:HP_0011476","obo:HP_0000698","obo:HP_0000691"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"cggv:a13ff342-794e-4b45-9803-7544026f5378_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:9c64d02c-54a5-49dd-9275-bd2906cd429c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005247.2(FGF3):c.283C>T (p.Arg95Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/38385"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21306635"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21306635","rdfs:label":"PKDF817 Proband"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5,"dc:description":"Variant is present in 1/30616 (0.003%) South Asian alleles in gnomAD. Downgraded because family is consanguineous"}],"specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:5ca11e8c-6703-4be5-a8c2-82e6dcc865e4_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:5ca11e8c-6703-4be5-a8c2-82e6dcc865e4_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:32813086-4288-4ac9-a8ec-43f284df22da","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:25bb0bc4-f722-4410-8611-4e252c08487e","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"Fgf3 is expressed continuously throughout otocyst development, and is likely one of two (the other Fgf10) relevant FDFR2b ligand-encoding genes for early otic morphogenesis. Fgf3 conditional knockout mice embryos have normal ears, normal auditory thresholds and normal motor behavior (data not shown in paper, so not counted as a mouse model). Conditional Fgf10 KO mice have vestibular and cochlear abnormalities. The authors suggest a crucial role for fgf3 expression in the hindbrain. Fgf3 and Fgf10 conditional KO blocks both vestibular and cochlear development","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/30504125","type":"dc:BibliographicResource","dc:abstract":"Morphogenesis of the inner ear epithelium requires coordinated deployment of several signaling pathways, and disruptions cause abnormalities of hearing and/or balance. The FGFR2b ligands FGF3 and FGF10 are expressed throughout otic development and are required individually for normal morphogenesis, but their prior and redundant roles in otic placode induction complicates investigation of subsequent combinatorial functions in morphogenesis. To interrogate these roles and identify new effectors of FGF3 and FGF10 signaling at the earliest stages of otic morphogenesis, we used conditional gene ablation after otic placode induction, and temporal inhibition of signaling with a secreted, dominant-negative FGFR2b ectodomain. We show that both ligands are required continuously after otocyst formation for maintenance of otic neuroblasts and for patterning and proliferation of the epithelium, leading to normal morphogenesis of both the cochlear and vestibular domains. Furthermore, the first genome-wide identification of proximal targets of FGFR2b signaling in the early otocyst reveals novel candidate genes for inner ear development and function.","dc:creator":"Urness LD","dc:date":"2018","dc:title":"Spatial and temporal inhibition of FGFR2b ligands reveals continuous requirements and novel targets in mouse inner ear morphogenesis."},"rdfs:label":"Urness Expression"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1,"dc:description":"Upgraded for including multiple conditional knock-out mouse models relevant to understanding the function of Fgf3"},{"id":"cggv:737f40ec-1f86-49c4-b0a6-457e24ec82c9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:0184aa0a-3ada-4ba6-b8e7-20118beffa22","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"Authors mapped the expression pattern of Fgf3 at stages HH20, HH24, HH27 and HH34 of otic placode formation in chick embryos","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26995070","type":"dc:BibliographicResource","dc:abstract":"The inner ear is a morphologically complex sensory structure with auditory and vestibular functions. The developing otic epithelium gives rise to neurosensory and non-sensory elements of the adult membranous labyrinth. Extrinsic and intrinsic signals manage the patterning and cell specification of the developing otic epithelium by establishing lineage-restricted compartments defined in turn by differential expression of regulatory genes. FGF3 and FGF16 are excellent candidates to govern these developmental events. Using the chick inner ear, we show that Fgf3 expression is present in the borders of all developing cristae. Strong Fgf16 expression was detected in a portion of the developing vertical and horizontal pouches, whereas the cristae show weaker or undetected Fgf16 expression at different developmental stages. Concerning the rest of the vestibular sensory elements, both the utricular and saccular maculae were Fgf3 positive. Interestingly, strong Fgf16 expression delimited these Fgf16-negative sensory patches. The Fgf3-negative macula neglecta and the Fgf3-positive macula lagena were included within weakly Fgf16-expressing areas. Therefore, different FGF-mediated mechanisms might regulate the specification of the anterior (utricular and saccular) and posterior (neglecta and lagena) maculae. In the developing cochlear duct, dynamic Fgf3 and Fgf16 expression suggests their cooperation in the early specification and later cell differentiation in the hearing system. The requirement of Fgf3 and Fgf16 genes in endolymphatic apparatus development and neurogenesis are discussed. Based on these observations, FGF3 and FGF16 seem to be key signaling pathways that control the inner ear plan by defining epithelial identities within the developing otic epithelium.","dc:creator":"Olaya-SÃ¡nchez D","dc:date":"2017","dc:title":"Fgf3 and Fgf16 expression patterns define spatial and temporal domains in the developing chick inner ear."},"rdfs:label":"Chick Embryo Expression Map"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1,"dc:description":"upgraded for thorough expression study"},{"id":"cggv:7e3df6ac-3ed7-4100-846d-100c775376ff","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:5ea6e5ff-014a-47f9-8a88-dd2b9d5bffea","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionA"},"dc:description":"combined FGF10/FGF3 exposure to hiPSCs induces conversion to otic/placodal progenitor cells","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/29902227","type":"dc:BibliographicResource","dc:abstract":"The inner ear represents a promising system to develop cell-based therapies from human induced pluripotent stem cells (hiPSCs). In the developing ear, Notch signaling plays multiple roles in otic region specification and for cell fate determination. Optimizing hiPSC induction for the generation of appropriate numbers of otic progenitors and derivatives, such as hair cells, may provide an unlimited supply of cells for research and cell-based therapy. In this study, we used monolayer cultures, otic-inducing agents, Notch modulation, and marker expression to track early and otic sensory lineages during hiPSC differentiation. Otic/placodal progenitors were derived from hiPSC cultures in medium supplemented with FGF3/FGF10 for 13 days. These progenitor cells were then treated for 7 days with retinoic acid (RA) and epidermal growth factor (EGF) or a Notch inhibitor. The differentiated cultures were analyzed in parallel by qPCR and immunocytochemistry. After the 13 day induction, hiPSC-derived cells displayed an upregulated expression of a panel of otic/placodal markers. Strikingly, a subset of these induced progenitor cells displayed key-otic sensory markers, the percentage of which was increased in cultures under Notch inhibition as compared to RA/EGF-treated cultures. Our results show that modulating Notch pathway during in vitro differentiation of hiPSC-derived otic/placodal progenitors is a valuable strategy to promote the expression of human otic sensory lineage genes.","dc:creator":"Lahlou H","dc:date":"2018","dc:title":"Modeling human early otic sensory cell development with induced pluripotent stem cells."},"rdfs:label":"Lahlou Biochemical Function"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"cggv:5ca11e8c-6703-4be5-a8c2-82e6dcc865e4_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:5930f0db-2410-422d-ac4f-c0a511c53d3a","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:e9ad4031-4c50-45dd-ada8-54bebd2fe520","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"crossing of fgf3-null hets. resulted in mendelian expected ratio of embryos. Beginning at E12.5, all Fgf3-/- embryos were smaller than normal litermates and had visible tail defect: short, curl or kinked dorsally. Fgf3-/- embryos had developmental delay. Observed 18 of 168 pups born were homozygous KO mice, and had the tail defect. This is less than expected, and since there appeared to be little to no embryonic lethality, it is assumed that missing homozygous mutants were consumed by their mothers very shortly after birth. Of the 18 fgf3-/- mice, 11 lived for less than 2 days, and 7 lived for 2 days to 3 weeks.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/8223243","type":"dc:BibliographicResource","dc:abstract":"We derived mice that carry a targeted insertion of a neor gene in the int-2 (Fgf-3) proto-oncogene coding sequences. The mutation was found to be recessive and mice that were homozygous for the insertion did not often survive to adulthood. The mutant mice had defects in the development of the tail and inner ear that could be correlated with disruption of int-2 expression in the posterior primitive streak and hindbrain or otic vesicle. While the tail phenotype was 100% penetrant, we found that the inner ear phenotype had reduced penetrance and variable expressivity. The variable expressivity could not be attributed to variability in the genetic background of the mutant allele or to leaky expression from the mutant allele. Thus, we conclude that even in a uniform genetic background, stochastic variation in the expression of a developmental circuit can result in dramatic differences in phenotypic consequences.","dc:creator":"Mansour SL","dc:date":"1993","dc:title":"Mice homozygous for a targeted disruption of the proto-oncogene int-2 have developmental defects in the tail and inner ear."},"rdfs:label":"Mansour Mouse Embryo Model"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"cggv:e44bb605-5a55-4226-b565-9ac297337316","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:34cdd75b-2893-4562-a47b-d0d293ef9147","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"5 hom. KO females survived to weaning and 2 were tested for fertility. The mice were fertile and produced between them 9 normal het. pups and 7 hom. mutant pups with tail defect. one surviving homozygous mutant mouse showed circling behavior, head tilt, trouble righting after being placed on it's back, little or no ear movement, little startle response. Examination of the right ear: cochlea was improperly coiled, both cochlear duct and semicircular canals were enlarged, both cochlear and vestibular portions of inner ear developed sensory epithelia, spiral ganglia of cochlear hair cells were severely reduced in number. Left ear: more extremely affected than right ear, composed of two cochlear chambers lined with stria vascularis but only one developed the organ of Corti, no spiral ganglion cells were found","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8223243","rdfs:label":"Mansour Mouse Model"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":627,"specifiedBy":"GeneValidityCriteria6","strengthScore":18,"subject":{"id":"cggv:d028a7d6-2d7a-4f23-9c36-407edab66e53","type":"GeneValidityProposition","disease":"obo:MONDO_0012541","gene":"hgnc:3681","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"FGF3 was first reported in relation to autosomal recessive deafness with labyrinthine aplasia, microtia, and microdontiain (LAMM) syndrome  in 2007 (Tekin et al., PMID 17236138). At least 11 variants (e.g. missense, nonsense, frameshift) have been reported in humans. Evidence supporting this gene-disease relationship includes case-level data, segregation data, experimental data. Variants in this gene have been reported in at least 12 probands in 6 publications (PMIDs 21480479, 21306635, 18435799, 17236138, 21306635, 18701883). Variants in this gene segregated with disease in at least 41 additional family members. More evidence is available in the literature, but the maximum score for genetic evidence and experimental evidence (12 pts.) has been reached. The mechanism for disease appears to be homozygous loss of function based on the variants observed in patients. This gene-disease association is supported by animal models, expression studies and in vitro functional assays (PMIDs 8223243, 26995070, 29902227, 30504125). In summary, FGF3 is definitively associated with autosomal recessive deafness with LAMM syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Hearing Loss Expert Panel on 5/21/2019 (SOP Version 6).\n","dc:isVersionOf":{"id":"cggv:5ca11e8c-6703-4be5-a8c2-82e6dcc865e4"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}